Rho-kinase Inhibitors in Ocular Diseases: A Translational Research Journey.
Singh K, Singh A.
Singh K, et al. Among authors: singh a.
J Curr Glaucoma Pract. 2023 Jan-Mar;17(1):44-48. doi: 10.5005/jp-journals-10078-1396.
J Curr Glaucoma Pract. 2023.
PMID: 37228304
Free PMC article.
Review.
CONCLUSION: Moderate efficacy of ROCK inhibitors with a common side effect of conjunctival hyperemia, makes it an adjunctive antiglaucoma drug of choice and not a first-line therapy. ...The property of ROCK inhibition to stabilize the endothelium of both retinal vas …
CONCLUSION: Moderate efficacy of ROCK inhibitors with a common side effect of conjunctival hyperemia, makes it an adjunctive antiglau …